Send us a text

This conversation between Scott Friedman, Laurent Castera, Louise Campbell and Roger Green covers the four panelists’ general impressions of TLM2023, both the good and bad of it. 
Scott starts with a simple statement: “It was good to be at an AASLD that felt like an AASLD. Specifically, Scott is talking about the energy and excitement associated with the meeting. He also approves of Boston as a meeting location. 
Scott’s meeting worst was the meeting app. The group elaborates on why they all agree. 
Laurent Castera agrees with Scott: bad app; excellent meeting with a great deal of colleague interaction. 
As a virtual attendee, Louise felt her own unique pain with the app. In addition, only 20% of sessions were live, and many were Zoom, which meant ‘Zoom in the US.’ She describes this as the most disappointing meeting experience, and she notes that some people paid $1,200 for it. 
I make two other points: the patient tracks were broad in coverage and highly well-attended, and Saturday night’s Diwali celebration. Scott, Laurent and I agree that the meeting was genuinely crowded and hot…but worthwhile. 
My final comment: tremendous excitement and anticipation about March 14, resmetirom’s PDUFA date at the FDA.